Anavex Life Sciences Corp (AVXL)

[JB3729]

Safety is so important. A terrible safety profile is one of the reasons doctors are hesitant to prescribe donepezil. Another thing doctors don't like about donepezil is it's low chance of being effective in patients.

Everything I have read gives donepezil less than a 50% chance of helping patients. I've read as low as a 33% chance.

27 out of 32 (84%) of patients in the AVXL trial are still being dosed after 31 weeks. It makes sense to me that all 27 are receiving at least some benefit or else they would have dropped out.

Even if AVXL's trial is helping 70% of patients, it may still have a positive effect on twice as many patients as donepezil while sporting an excellent safety profile.

Which one would doctors prescribe?